Research On Overseas M&a Strategy Of Private Pharmaceutical Enterprises

The government has been building the Silk Road Economic Belt strategy and promoting domestic enterprises to go out actively.In order to support domestic enterprises to achieve international operations,the government has provided a number of service guarantees,regulatory guarantees,and management guarantees.The favorable policies have brought investment opportunities to domestic enterprises.At the same time,the global multinational pharmaceutical companies laid out their industries globally and developed in the direction of internationalization.With China's policy tilt and capital promotion,foreign multinational pharmaceutical giants have occupied half of China's pharmaceutical market,and domestic pharmaceutical companies are suffering business conflicts from international counterparts.How China's pharmaceutical companies achieve internationalization through overseas mergers and acquisitions,this research topic has pressing and practical significance.This article takes the overseas M&A of private pharmaceutical companies in China as the core issue,and conducts research on the development history,development status,strategic significance,existing risks,and countermeasures of Chinese pharmaceutical companies' overseas acquisitions.The case studies and empirical analysis are used to comprehensively analyze the merger and acquisition of Fosun Pharma.The study finds that the strategic motives of overseas M&A by private pharmaceutical companies is expanding overseas markets,access to high-tech,and industrial integration and integration,and the risk factors are legal risks,valuation risks,and integration risks.In the case of Fosun Pharma's acquisition of Alma Lasers,the incident research method,financial index method,and data envelopment method were used to analyze the performance of the merger and acquisition of Fosun Pharma.It was found that the efficiency of mergers and acquisitions was significantly improved.Combining the status quo of overseas M&A of pharmaceutical companies and the case study of Fosun Pharma,the following recommendations were made on the strategic choices of overseas M&As by private pharmaceutical companies in China:full use of government regulation and support,clear strategic objectives for overseas acquisitions,familiarity with the legal environment of the target country,establish and improve the risk prevention and control system,and actively promote the integration of M&A resources.